查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1089206

系統性紅斑狼瘡(SLE)全球市場：產品類型、給藥途徑、最終用戶、按地區劃分的規模、趨勢、COVID-19影響、預測~2026

Global Systemic Lupus Erythematosus (SLE) Market: Analysis By Product Type, By Route of Administration, By End User, By Region Size and Trends with Impact of COVID-19 and forecast up to 2026
出版日期: | 出版商: Daedal Research | 英文 135 Pages | 訂單完成後即時交付

價格

全球系統性紅斑狼瘡 (SLE) 市場將從 2021 年的 18.9 億美元增長到 2022-2026 年預測期間的 7.49% 和 2026 年的 27 億美元的複合年增長率。預計將增長到美國的規模1000萬美元。

系統性紅斑狼瘡 (SLE) 是一種非常延遲的治療方法，有效的治療方法有限。由於巨大的未滿足的醫療需求，預計未來市場將擴大。

本報告探討了全球系統性紅斑狼瘡 (SLE) 市場，分析了市場概況、新型冠狀病毒感染 (COVID-19) 等市場影響因素，以及市場規模的變化。預測、按類別/地區細分、競爭力環境、大公司概況等匯總。

目錄

第 1 章執行摘要

第二章介紹

第三章世界市場分析

  • 全球系統性紅斑狼瘡 (SLE) 市場：分析
    • 全球系統性紅斑狼瘡 (SLE) 市場（數量）
    • 按患者人數
    • 按產品類型（生物製劑、非甾體抗炎藥、抗瘧疾藥物、皮質類固醇、免疫抑製劑等）
    • 通過給藥途徑（口服、靜脈內、皮下）
    • 最終用戶（醫院、藥物實驗室等）
    • 按地區（北美/歐洲/亞太地區/拉丁美洲/中東和非洲）
  • 全球系統性紅斑狼瘡 (SLE) 市場：按產品分類
    • 生物製藥
    • 非甾體抗炎藥
    • 抗瘧藥
    • 皮質類固醇
    • 免疫抑製劑
    • 其他
  • 全球系統性紅斑狼瘡 (SLE) 市場：按給藥途徑
    • 口腔
    • 靜脈注射
    • 皮下
  • 全球系統性紅斑狼瘡 (SLE) 市場：按最終用戶分類
    • 醫院
    • 藥物實驗室
    • 其他

第四章區域市場分析

  • 北美
  • 歐洲
  • 亞太地區
  • 中東/非洲
  • 拉丁美洲

第 5 章 COVID-19 的影響

第6章市場動態

  • 生長因子
  • 挑戰
  • 趨勢

第7章競爭態勢

  • 主要美國和中國公司：推出生物製藥
  • 主要的美國和中國公司：管道生物製藥

第 8 章公司簡介

  • Hoffmann-LA- Roche Ltd.
  • Pfizer, Inc.
  • AbbVie, Inc.
  • Novartis AG
  • AstraZeneca Plc
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • UCB SA
  • RemeGen Co., Ltd.
  • Amgen Inc.
  • Biotest AG
  • Xencor, Inc.
  • Sanofi
  • Boston Pharmaceuticals

In 2021, the global systemic lupus erythematosus market was valued at US$1.89 billion. The market is projected to reach US$2.71 billion by 2026. Systemic Lupus Erythematosus (SLE) is a multi-systemic, incurable autoimmune disease with symptoms affecting nearly every organ and organ system in the human body. In this disease, the immune system targets the body's own tissues, resulting in extensive inflammation and tissue destruction in the organs involved. Some of the most common symptoms of SLE are swollen joints, unexplained fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, excessive exhaustion, and red rashes on the face.

SLE is a very undertreated disease with limited effective therapeutic options globally. The only available biologic therapy approved in this indication globally are GSK's Benlysta (approved by US FDA 2011 and China's NMPA in 2019), Astra Zeneca's Saphnelo (approved by the FDA in August 2021) and RemeGen's telitacicept (approved by China's NMPA in 2021). However, with significant unmet medical need, the market would grow in the years to come. The systemic lupus erythematosus market is expected to grow at a CAGR of 7.49% over the forecasted years 2022-2026.

Market Segmentation Analysis:

By Product Type: The report identifies six segments on the basis of Product Type: Biologics, NSAIDs, Antimalarial Drugs, Corticosteroids, Immunosuppressants and Others. In 2021, the biologics segment lead the market accounted for 33.7% share of the market. Demand for drugs with better efficacy and safety profile have increased among people. Biologics are safer than many other products, and can be used to treat women during pregnancy. The market is expected to grow at the highest CAGR, due to technological advancements in biologics. For instance, gene-based and cellular biologics are frequently at the forefront of biomedical research and may be utilized to treat a number of medical problems for which no other treatments exist.

By Route of Aministration: The report includes bifurcation of the market into three segments on the basis of route of aministration: Oral, Intravenous and Subcutaneous. The oral segment dominated the market by occupying almost half of the share of the market in 2021. Oral route of administration is convenient, safe and cost effective. Therefore, on most of the times, people prefer to use oral route of administration in SLE treatment. Subcutaneous segment is projected to grow at the highest CAGR of 8.62% over the forecast period. Subcutaneous is a good route of administration especially in skin infections.

By End User: The report includes bifurcation of the market into three segments on the basis end user: Hospitals, Drug Lab and Others. The hospital segment dominated the market with 46.7% share of the market in 2021. The hospital segment is expected to grow rapidly due to initiatives taken by several government around the world. Some hospitals are also providing free treatment to the SLE patients. Drug labs are commonly used for research and development of new drugs. Demand for drugs is increasing with increasing number od SLE patients and therefore drug lab segment would also grow in the coming years.

By Region: In the report, the global systemic lupus erythematosus market is divided into five regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America dominated the market in 2021, by occupying around 44.4% share of the global market. Factors such as increasing prevalence of lupus and presence of prominent players have supported the growth of the systemic lupus erythematosus market in the region. North America systemic lupus erythematosus market provides lucrative opportunities in the coming years. Economic stability, government initiatives and presence of various market players in the region gives a resilient opportunity for Systemic Lupus Erythematosus market.

Market Dynamics:

Growth Drivers: The market has been growing over the past few years, due to factors such as increasing healthcare expenditure, increasing female population, rapid urbanization, favorable Government initiatives, rising prevalence of SLE disease, etc. Several initiatives are taken by various organizations and government to aware people about SLE. With government support, various research institutes are providing drugs and therapies to the SLE patients. Several new drugs are under trial which are funded by government. The Centers for Disease Control and Prevention (CDC) in the US is regularly releasing SLE disease statistics and warning citizens about the severe consequences of the disease, especially in women population.

Challenges: However, the market has been confronted with some challenges specifically, stringent regulatory environment, high cost of drug development, etc. Stringent regulatory environment is one of the major challenges to the systemic lupus erythematosus market. Traditionally, all vaccinations, medical gadgets, and helpful medications developed to treat certain diseases have undergone extensive testing in clinical trials to ensure their safety and feasibility in treating the disease. These trials are very time consuming and rules and regulations associated with it are very stringent. Due to this reason, research organizations or pharmaceutical companies have to experience slow progress towards regulatory approvals. The strict regulations would restrain the growth of the market.

Trends: The market is projected to grow at a fast pace during the forecast period, due to various latest trends such as rising clinical trials, adoption of stem cell therapy, rising awareness among people, etc. For the treatment of Lupus, stem cell therapy may be one of the most promising new dimensions of medicine, especially for those who do not respond well to more traditional kinds of treatment. Adoption of Stem cell therapy is increasing because this is a new and advance technique to treat lupus and that would boost the SLE market growth.

Impact Analysis of COVID-19 and Way Forward:

In the early phases of the pandemic, the world was put under lockdown to stop the virus from spreading, suspending the majority of commercial operations. The lockdown had a huge influence on industries that are considered the backbone of the world economy, such as manufacturing, aviation, tourism, and so on, causing the global economy to enter a recession. The healthcare businesses encountered a number of challenges during the early stages of the pandemic. The availability of doctors, health workers as well as the supply of medical devices, diagnostics, and treatments, were all affected. Regular identification and treatment of other diseases were missed in the first half of 2020, because entire healthcare sector was focused on preventing, detecting and treating COVID-19.

On the contrary, as the lockdowns were gradually released near the second half of 2020, there was an increase in the number of patients seeking treatment for autoimmune diseases. Healthcare sector restored to normal as rate of transmission was reduced. Treatment for autoimmune diseases began at a better pace. As a result, COVID-19 had a short-term detrimental impact on the systemic lupus erythematosus market.

Competitive Landscape:

Most of the approved therapies for SLE are small molecule immunosuppressive agents such as azathioprine (first approved by the FDA in 1968), mycophenolate mofetil (first approved by the FDA in 1995) and methotrexate (first approved by the FDA in 1953), all of which are now off-patent and being marketed by multiple pharmaceutical companies in generic forms.

Beyond these small molecule drugs, there are currently two biologic drugs approved for the treatment of SLE globally: GSK's belimumab (approved by the FDA in 2011 and NMPA in 2019) and RemeGen's Telitacicept (approved by the NMPA in 2021 and not approved yet in the US). Beyond these two approved products, there are two innovative biologics for the treatment of SLE in phase III development in the US (along with eighteen other molecules in Phase I/II) and no Phase III pipeline assets in China (but five assets in Phase I/II).

The key players of the global systemic lupus erythematosus market are:

Hoffmann-LA-Roche Ltd.

Pfizer, Inc.

Abbvie, Inc.

Novartis AG

AstraZeneca Plc

GlaxoSmithKline Plc

Merck & Co., Inc.

UCB SA

RemeGen Co., Ltd.

Amgen Inc.

Biotest AG

Xencor, Inc.

Sanofi

Boston Pharmaceuticals

Hoffmann-LA-Roche Ltd., Pfizer, Inc., Abbvie, Inc. are some of the major drug manufacturer and have a dominance around the world. However, company like AstraZeneca Plc has a strong presence in the vaccine development and manufacturing as well. GlaxoSmithKline plc. is also a significant participant in the market with segments like pharmaceuticals, consumer healthcare, vaccine, etc.

Scope of the Report:

The report titled "Global Systemic Lupus Erythematosus Market: Analysis By Product Type, By Route of Administration, By End User, By Region Size and Trends with Impact of COVID-19 and forecast up to 2026", includes:

- An in-depth analysis of the global systemic lupus erythematosus market by product type, by route of administration, by end user, by region, etc.

- The regional analysis of the systemic lupus erythematosus market, including the following regions:

North America (The US, Mexico and Canada)

Europe (UK, Germany, France, Spain, Italy and Rest of Europe)

Asia Pacific

Middle East & Africa

Latin America

- Comprehensive information about emerging markets. This report analyses the market for various segments across geographies.

- Provides an analysis of the COVID-19 impact on the global systemic lupus erythematosus market.

- Assesses the key opportunities in the market and outlines the factors that are and would be driving the growth of the industry. Growth of the overall systemic lupus erythematosus market has also been forecasted for the period 2022-2026, taking into consideration the previous growth patterns, the growth drivers, and the current and future trends.

- Evaluation of the potential role of systemic lupus erythematosus to improve the market status.

- Identification of new technological developments, R&D activities, and product launches occuring in the systemic lupus erythematosus market.

- In-depth profiling of the key players, including the assessment of the business overview, market strategies, regional and business segments of the leading players in the market.

- The recent developments, mergers and acquisitions related to mentioned key players are provided in the market report.

- The in-depth analysis provides an insight into the market, underlining the growth rate and opportunities offered in the business.

Table of Contents

    1. Executive Summary

    2. Introduction

    • 2.1 Systemic Lupus Erythematosus (SLE): An Overview
    • 2.2 Systemic Lupus Erythematosus (SLE) Segmentation: An Overview

    3. Global Market Analysis

    • 3.1 Global Systemic Lupus Erythematosus Market: An Analysis
      • 3.1.1 Global Systemic Lupus Erythematosus Market by Value
      • 3.1.2 Global Systemic Lupus Erythematosus Market by Number of Patients
      • 3.1.3 Global Systemic Lupus Erythematosus Market by Product Type (Biologics, NSAIDs, Antimalarial Drugs, Corticosteroids, Immunosuppressants and Others)
      • 3.1.4 Global Systemic Lupus Erythematosus Market by Route of Administration (Oral, Intravenous and Subcutaneous)
      • 3.1.5 Global Systemic Lupus Erythematosus Market by End User (Hospitals, Drug Lab and Others)
      • 3.1.6 Global Systemic Lupus Erythematosus Market by Region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa)
    • 3.2 Global Systemic Lupus Erythematosus Market: Product Analysis
      • 3.2.1 Global Biologics Systemic Lupus Erythematosus Market by Value
      • 3.2.2 Global NSAIDs Systemic Lupus Erythematosus Market by Value
      • 3.2.3 Global Antimalarial Drugs Systemic Lupus Erythematosus Market by Value
      • 3.2.4 Global Corticosteroids Systemic Lupus Erythematosus Market by Value
      • 3.2.5 Global Immunosuppressant Systemic Lupus Erythematosus Market by Value
      • 3.2.6 Global Others Systemic Lupus Erythematosus Market by Value
    • 3.3 Global Systemic Lupus Erythematosus Market: Route of Administration Analysis
      • 3.3.1 Global Oral Systemic Lupus Erythematosus Market by Value
      • 3.3.2 Global Intravenous Systemic Lupus Erythematosus Market by Value
      • 3.3.3 Global Subcutaneous Systemic Lupus Erythematosus Market by Value
    • 3.4 Global Systemic Lupus Erythematosus Market: End User Analysis
      • 3.4.1 Global Hospitals Systemic Lupus Erythematosus Market by Value
      • 3.4.2 Global Drug Lab Systemic Lupus Erythematosus Market by Value
      • 3.4.3 Global Others Systemic Lupus Erythematosus Market by Value

    4. Regional Market Analysis

    • 4.1 North America Systemic Lupus Erythematosus Market: An Analysis
      • 4.1.1 North America Systemic Lupus Erythematosus Market by Value
      • 4.1.2 North America Systemic Lupus Erythematosus Market by Region (The US, Canada and Mexico)
      • 4.1.3 The US Systemic Lupus Erythematosus Market by Value
      • 4.1.4 The US Systemic Lupus Erythematosus Market by Number of Patients
      • 4.1.5 Canada Systemic Lupus Erythematosus Market by Value
      • 4.1.6 Mexico Systemic Lupus Erythematosus Market by Value
    • 4.2 Europe Systemic Lupus Erythematosus Market: An Analysis
      • 4.2.1 Europe Systemic Lupus Erythematosus Market by Value
      • 4.2.2 Europe Systemic Lupus Erythematosus Market by Region (UK, Germany, France, Spain, Italy and Rest of Europe)
      • 4.2.3 UK Systemic Lupus Erythematosus Market by Value
      • 4.2.4 Germany Systemic Lupus Erythematosus Market by Value
      • 4.2.5 France Systemic Lupus Erythematosus Market by Value
      • 4.2.6 Spain Systemic Lupus Erythematosus Market by Value
      • 4.2.7 Italy Systemic Lupus Erythematosus Market by Value
      • 4.2.8 Rest of Europe Systemic Lupus Erythematosus Market by Value
    • 4.3 Asia pacific Systemic Lupus Erythematosus Market: An Analysis
      • 4.3.1 Asia pacific Systemic Lupus Erythematosus Market by Value
    • 4.4 Middle East & Africa Systemic Lupus Erythematosus Market: An Analysis
      • 4.4.1 Middle East & Africa Systemic Lupus Erythematosus Market by Value
    • 4.5 Latin America Systemic Lupus Erythematosus Market: An Analysis
      • 4.5.1 Latin America Systemic Lupus Erythematosus Market by Value

    5. Impact of COVID-19

    • 5.1 Impact of COVID-19
      • 5.1.1 Impact of COVID-19 on Healthcare
      • 5.1.2 Impact of COVID-19 on Systemic Lupus Erythematosus Market

    6. Market Dynamics

    • 6.1 Growth Drivers
      • 6.1.1 Increasing Healthcare Expenditure
      • 6.1.2 Increasing Female Population
      • 6.1.3 Rapid Urbanization
      • 6.1.4 Favorable Government Initiatives
      • 6.1.5 Rising Prevalence of SLE Disease
    • 6.2 Challenges
      • 6.2.1 Stringent Regulatory Environment
      • 6.2.2 High Cost of Drug Development
    • 6.3 Trends
      • 6.3.1 Rising Clinical Trials
      • 6.3.2 Adoption of Stem Cell Therapy
      • 6.3.3 Rising Awareness Among People

    7. Competitive Landscape

    • 7.1 The US and China Systemic Lupus Erythematosus Market Players by Marketed Biologics for SLE Treatment
    • 7.2 The US and China Systemic Lupus Erythematosus Market players by Pipeline Biologics for SLE Treatment

    8. Company Profiles

    • 8.1 Hoffmann-LA- Roche Ltd.
      • 8.1.1 Business Overview
      • 8.1.2 Operating Segments
      • 8.1.3 Business Strategies
    • 8.2 Pfizer, Inc.
      • 8.2.1 Business Overview
      • 8.2.2 Operating Segments
      • 8.2.3 Business Strategies
    • 8.3 AbbVie, Inc.
      • 8.3.1 Business Overview
      • 8.3.2 Operating Segments
      • 8.3.3 Business Strategies
    • 8.4 Novartis AG
      • 8.4.1 Business Overview
      • 8.4.2 Operating Segments
      • 8.4.3 Business Strategies
    • 8.5 AstraZeneca Plc
      • 8.5.1 Business Overview
      • 8.5.2 Operating Segments
      • 8.5.3 Business Strategies
    • 8.6 GlaxoSmithKline plc
      • 8.6.1 Business Overview
      • 8.6.2 Operating Segments
      • 8.6.3 Business Strategies
    • 8.7 Merck & Co., Inc.
      • 8.7.1 Business Overview
      • 8.7.2 Operating Segments
      • 8.7.3 Business Strategies
    • 8.8 UCB SA
      • 8.8.1 Business Overview
      • 8.8.2 Operating Regions
      • 8.8.3 Business Strategies
    • 8.9 RemeGen Co., Ltd.
      • 8.9.1 Business Overview
      • 8.9.2 Operating Regions
      • 8.9.3 Business Strategies
    • 8.10 Amgen Inc.
      • 8.10.1 Business Overview
      • 8.10.2 Operating Region
      • 8.10.3 Business Strategies
    • 8.11 Biotest AG
      • 8.11.1 Business Overview
      • 8.11.2 Operating Segments
      • 8.11.3 Business Strategies
    • 8.12 Xencor, Inc.
      • 8.12.1 Business Overview
      • 8.12.2 Revenue By Operations
      • 8.12.3 Business Strategies
    • 8.13 Sanofi
      • 8.13.1 Business Overview
      • 8.13.2 Operating Segments
      • 8.13.3 Business Strategies
    • 8.14 Boston Pharmaceuticals
      • 8.14.1 Business Overview
      • 8.14.2 Business Strategies

List of Tables

  • Table 1: The US and China Systemic Lupus Erythematosus Market Players by Marketed Biologics for SLE Treatment
  • Table 2: The US and China Systemic Lupus Erythematosus Market Players by Pipeline Biologics for SLE Treatment

List of Figures

  • Figure 1: Systemic Lupus Erythematosus (SLE) Segmentation
  • Figure 2: Global Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Billion)
  • Figure 3: Global Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Billion)
  • Figure 4: Global Systemic Lupus Erythematosus Market by Number of Patients; 2020-2021 (Million)
  • Figure 5: Global Systemic Lupus Erythematosus Market by Number of Patients; 2022-2026 (Million)
  • Figure 6: Global Systemic Lupus Erythematosus Market by Product Type; 2021 (Percentage, %)
  • Figure 7: Global Systemic Lupus Erythematosus Market by Route of Administration; 2021 (Percentage, %)
  • Figure 8: Global Systemic Lupus Erythematosus Market by End User; 2021 (Percentage, %)
  • Figure 9: Global Systemic Lupus Erythematosus Market by Region; 2021 (Percentage, %)
  • Figure 10: Global Biologics Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
  • Figure 11: Global Biologics Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 12: Global NSAIDs Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
  • Figure 13: Global NSAIDs Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 14: Global Antimalarial Drugs Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
  • Figure 15: Global Antimalarial Drugs Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 16: Global Corticosteroids Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
  • Figure 17: Global Corticosteroids Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 18: Global Immunosuppressant Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
  • Figure 19: Global Immunosuppressant Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 20: Global Others Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
  • Figure 21: Global Others Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 22: Global Oral Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
  • Figure 23: Global Oral Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Billion)
  • Figure 24: Global Intravenous Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
  • Figure 25: Global Intravenous Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 26: Global Subcutaneous Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
  • Figure 27: Global Subcutaneous Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 28: Global Hospitals Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
  • Figure 29: Global Hospitals Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 30: Global Drug Lab Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
  • Figure 31: Global Drug Lab Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 32: Global Others Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
  • Figure 33: Global Others Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 34: North America Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
  • Figure 35: North America Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 36: North America Systemic Lupus Erythematosus Market by Region; 2021 (Percentage, %)
  • Figure 37: The US Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
  • Figure 38: The US Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 39: The US Systemic Lupus Erythematosus Market by Number of Patients; 2020-2021 (Thousand)
  • Figure 40: The US Systemic Lupus Erythematosus Market by Number of Patients; 2022-2026 (Thousand)
  • Figure 41: Canada Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
  • Figure 42: Canada Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 43: Mexico Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
  • Figure 44: Mexico Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 45: Europe Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
  • Figure 46: Europe Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 47: Europe Systemic Systemic Lupus Erythematosus Market by Region; 2021 (Percentage, %)
  • Figure 48: UK Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
  • Figure 49: UK Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 50: Germany Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
  • Figure 51: Germany Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 52: France Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
  • Figure 53: France Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 54: Spain Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
  • Figure 55: Spain Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 56: Italy Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
  • Figure 57: Italy Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 58: Rest of Europe Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
  • Figure 59: Rest of Europe Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 60: Asia pacific Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
  • Figure 61: Asia pacific Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 62: Middle East & Africa Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
  • Figure 63: Middle East & Africa Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 64: Latin America Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
  • Figure 65: Latin America Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
  • Figure 66: The US Health Consumption Expenditure as a Percentage of GDP; 2015-2020 (Percentage, %)
  • Figure 67: Global Female Population of Age Group 15-44; 2005-2020 (Billion)
  • Figure 68: Global Urban Population as a Share of Total Population; 2016-2021 (Percentage, %)
  • Figure 69: Hoffmann-La-Roche Ltd. Sales by Business Divisions; 2021 (Percentage, %)
  • Figure 70: Pfizer Inc. Revenues by Operating Segments; 2021 (Percentage, %)
  • Figure 71: Abbvie, Inc. Net Revenues by Products; 2021 (Percentage, %)
  • Figure 72: Novartis AG Net Sales by Segment; 2021 (Percentage, %)
  • Figure 73: AstraZeneca Plc Total Revenue by Product; 2021 (Percentage, %)
  • Figure 74: GlaxoSmithKline plc Turnover by Segments; 2021 (Percentage, %)
  • Figure 75: Merck & Co., Inc. Total Sales by Segments; 2021 (Percentage, %)
  • Figure 76: UCB SA Net Sales by Region; 2021 (Percentage, %)
  • Figure 77: RemeGen Co., Ltd. Revenue by Region; 2021 (Percentage, %)
  • Figure 78: Amgen Inc. Revenue by Region; 2021 (Percentage, %)
  • Figure 79: Biotest AG Sales by Segment; 2021 (Percentage, %)
  • Figure 80: Xencor, Inc. Revenue by Operations; 2021 (Percentage, %)
  • Figure 81: Sanofi Net Sales by segments; 2021 (Percentage, %)